Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of a Combination COVID-19 and High-dose Influenza Vaccine in Adults 50+
NCT06695117Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rC19 and influenza vaccine (quadrivalent, high-dose) in coronavirus disease 2019 (COVID-19) and influenza (7 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate adverse events at 30 minutes, Number of participants with solicited injection site reactions at 7 days and 12 more. Started Nov 2024; status: completed.
02
Drugs
rC19influenza vaccine (quadrivalent, high-dose)
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06695117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695117.